Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents

References

• Almond S, Knapp M, Francois C, et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004;184:346-51
   PubMed Web of Science ®Google Scholar
• Harvey PD, Heaton RK, Carpenter WT Jr, et al. Functional impairment in people with schizophrenia: focus on employability and eligibility for disability compensation. Schizophr Res 2012;140:1-8
   PubMed Web of Science ®Google Scholar
• Maj M, Sartorius N (eds). Economics of schizophrenia: a review, 2nd edn. Chichester: John Wiley and Sons, 2002
   Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64
   PubMed Web of Science ®Google Scholar
• Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-9
   PubMed Web of Science ®Google Scholar
• Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry 2011;72(Suppl 1):4-8
   PubMed Web of Science ®Google Scholar
• Voruganti LP, Baker LK, Awad AG. New generation antipsychotic drugs and compliance behaviour. Curr Opin Psychiatry 2008;21:133-9
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Levine SZ, Barkai O, et al. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull 2009;35:775-88
   PubMed Web of Science ®Google Scholar
• Falkai P. Limitations of current therapies: why do patients switch therapies? Eur Neuropsychopharmacol 2008;18(Suppl 3):S135-9
   PubMedGoogle Scholar
• Weber M, Gutierrez AM, Mohammadi M. The risks and benefits of switching antipsychotics: a case study approach. Perspect Psychiatr Care 2009;45:54-61
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600-10
   PubMed Web of Science ®Google Scholar
• Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009;23:649-59
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611-22
   PubMed Web of Science ®Google Scholar
• Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetic and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 2005;15(Suppl 3):S385
   Google Scholar
• Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin 2006;22:1879-92
   PubMed Web of Science ®Google Scholar
• Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
   PubMed Web of Science ®Google Scholar
• Buckley PF, Miller BJ, Lehrer DS, et al. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009;35:383-402
   PubMed Web of Science ®Google Scholar
• Vermeir M, Boom S, Naessens I, et al. Absorption, metabolism and excretion of a single oral dose of 14C-paliperidone 1mg in healthy subjects. Eur Neuropsychopharmacol 2005;15(Suppl 3):S648
   Google Scholar
• Canuso CM, Youssef EA, Bossie CA, et al. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. Int Clin Psychopharmacol 2008;23:209-15
   PubMed Web of Science ®Google Scholar
• Schreiner A, Hoeben D, Lahaye M, et al. P03-128 – a flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral risperidone. Eur Psychiatr 2010;25:1108
   Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007;93:117-30
   PubMed Web of Science ®Google Scholar
• Marder SR, Kramer M, Ford L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007;62:1363-70
   PubMed Web of Science ®Google Scholar
• Emsley R, Berwaerts J, Eerdekens M, et al. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 2008;23:343-56
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr Q 1994;65:299-322
   PubMedGoogle Scholar
• Yi JS, Ahn YM, Shin HK, et al. Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 2001;40:1090-105
   Google Scholar
• Haro JM, Kamath SA, Ochoa S, et al. The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003;416:16-23
   PubMedGoogle Scholar
• Lee JG, Seok JH, Lee JY, et al. A validation study of the Korean-version of the Personal and Social Performance Scale. Korean J Psychophamacol 2006;17:497-506
   Google Scholar
• Morosini PL, Magliano L, Brambilla L, et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-9
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burns T, Morosini P, et al. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009;25:325-38
   PubMed Web of Science ®Google Scholar
• Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79-88
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. A validation study of the Korean version of the Subjective Well-being Under Neuroleptic Treatment Scale–Short Form. Korean J Psychopharmacol 2007;18:221-30
   Google Scholar
• Inada T. Recent research trends in diagnosis, treatment, and prevention of drug-induced extrapyramidal symptoms seen in psychiatric patients. Nihon Shinkei Seishin Yakurigaku Zasshi 1996;16:181-5
   PubMedGoogle Scholar
• Day JC, Wood G, Dewey M, et al. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 1995;166:650-3
   PubMed Web of Science ®Google Scholar
• Jung HY, Joo YH, Shin HK, et al. A validation study of Korean-version of Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS). J Korean Neuropsychiatr Assoc 2002;41:138-45
   Google Scholar
• Canuso CM, Bossie CA, Turkoz I, et al. Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009;113:56-64
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Bobo WV, Nuamah IF, et al. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry 2008;69:817-29
   PubMed Web of Science ®Google Scholar
• Tzimos A, Samokhvalov V, Kramer M, et al. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry 2008;16:31-43
   PubMed Web of Science ®Google Scholar
• Wolters HA, Knegtering H, van den Bosch RJ, et al. Effects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophr Res 2009;112:114-18
   PubMed Web of Science ®Google Scholar
• Lambert M, Schimmelmann BG, Schacht A, et al. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr Res 2009;107:165-72
   PubMed Web of Science ®Google Scholar
• Wehmeier PM, Kluge M, Schacht A, et al. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res 2007;91:178-86
   PubMed Web of Science ®Google Scholar
• Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006;86:234-43
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97
   PubMed Web of Science ®Google Scholar
• Harrington CA, English C. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. Int Clin Psychopharmacol 2010;25:334-41
   PubMed Web of Science ®Google Scholar
• Levine SZ, Rabinowitz J, Ascher-Svanum H, et al. Comparing symptom response among antipsychotic medications in CATIE. J Clin Psychopharmacol 2013;33:123-6
   PubMed Web of Science ®Google Scholar
• Levine SZ, Rabinowitz J, Ascher-Svanum H, et al. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res 2011;133:42-6
   PubMed Web of Science ®Google Scholar
• Levine SZ, Rabinowitz J, Faries D, et al. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial. Schizophr Res 2012;137:141-6
   PubMed Web of Science ®Google Scholar